ZVRA CEO McFarlane sells 91,000 shares at $9.38; stock now -26.8% from 52-week high, company unprofitable with -14.0% revenue decline
Neil F. McFarlane, President and CEO, sold 91,000 shares (91.0K shares) of ZEVRA THERAPEUTICS on 2026-02-02 at $9.38, reducing his holdings by 20.0% from 455,350 shares to 364,350 shares. The transaction comes as ZVRA shares trade 26.8% below their 52-week high of $12.79, while the company reported negative net income of $-544,000.00 in its latest quarter and experienced annual revenue decline of -14.0% year-over-year. McFarlane's prior sales at ZVRA in February 2025 saw the stock subsequently rise 3.6%–4.7% over the following 90 days, suggesting his past sales at this ticker did not precede material declines; the current sale occurs against deteriorating fundamentals (ongoing unprofitability and shrinking revenues) and near the lower bound of the stock's recent range.
ZVRA CEO McFarlane sells 91,817 shares in 2 transactions for $727,389.76; retains 191,516 shares post-sale amid -$33.2M net income.
CEO Neil F. McFarlane executed two separate sales totaling 91,817 shares for $727,389.76, reducing his holdings by 32.4% from 283,333 to 191,516 shares. The sales occurred at $7.86 and $8.05 per share on consecutive trading days, with a blended average of $7.92 against the current price of $8.07. The timing of this substantial disposition follows a period of significant revenue growth (+162.6% year-over-year) but amid persistent unprofitability: the company reported a net income of -$33.2M on quarterly revenue of $3.7M. The sale represents material liquidation by the chief executive while the company remains deeply loss-making, warranting investor review of whether operating metrics justify the growth trajectory.
